[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559144":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":41,"responsibleParty":139,"collaborators":37,"id":141,"slug":142,"hasResults":143,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":143,"sex":149,"minAge":150,"maxAge":151,"enrollmentInfo":152,"targetDuration":37,"studyType":155,"phases":156,"briefSummary":158,"conditions":159,"keywords":163,"overallStatus":44,"whyStopped":37,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},{"fullName":5,"class":6},"Enterra Medical, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Programming Stimulation","ACTIVE_COMPARATOR","Begin with nominal (lower stimulation) programming settings at Enterra Therapy System implantation. At treatment assignment, nominal programming will continue. Slight increases in device amplitude (stimulation) will be done at 3 Month visit and at later follow-up visits.",[13],"Device: Enterra Therapy System",{"label":15,"type":16,"description":17,"interventionNames":18},"Enhanced Programming Stimulation","EXPERIMENTAL","Begin with nominal (lower stimulation) programming settings at Enterra Therapy System implantation. At treatment assignment, moderate increases in device amplitude (stimulation) and duty cycle (on\u002Foff cycles) will be done. Further adjustments to amplitude, duty cycle, and\u002For frequency (rate of pulses) will be done at follow-up visits.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Enterra Therapy System","The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.",[9,15],[26],"Gastric electrical stimulation",[28],{"name":29,"affiliation":30,"role":31},"Michael Awad, MD, PhD","Washington University School of Medicine","PRINCIPAL_INVESTIGATOR",[33,39],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Timothy McAllister","CONTACT","855-768-3772",null,"clinicalresearch@enterramedical.com",{"name":40,"role":35,"phone":36,"phoneExt":37,"email":38},"Jason Hamann, PhD",[42,63,78,95,109,124],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"University of South Florida","RECRUITING","Tampa","Florida","33620","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-82.45843,27.94752,{"lat":54,"lon":53},[57,61],{"name":58,"role":35,"phone":59,"phoneExt":37,"email":60},"Beth Montera","(813)844-7948","bmontera@usf.edu",{"name":62,"role":35,"phone":37,"phoneExt":37,"email":37},"Joseph Sujka, MD",{"facility":64,"status":44,"city":65,"state":66,"zip":67,"country":48,"countryCode":49,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"University of Louisville","Louisville","Kentucky","40202",{"type":51,"coordinates":69},[70,71],-85.75941,38.25424,{"lat":71,"lon":70},[74,76],{"name":75,"role":35,"phone":37,"phoneExt":37,"email":37},"Amy Perdue",{"name":77,"role":35,"phone":37,"phoneExt":37,"email":37},"Abigail Stocker, MD",{"facility":79,"status":44,"city":80,"state":81,"zip":82,"country":48,"countryCode":49,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Henry Ford Health System","Detroit","Michigan","48202",{"type":51,"coordinates":84},[85,86],-83.04575,42.33143,{"lat":86,"lon":85},[89,93],{"name":90,"role":35,"phone":91,"phoneExt":37,"email":92},"Daniel Molitor","(313)-916-8194","dmolito2@hfhs.org",{"name":94,"role":35,"phone":37,"phoneExt":37,"email":37},"Kellie McFarlin, MD",{"facility":96,"status":44,"city":97,"state":98,"zip":99,"country":48,"countryCode":49,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Washington University","St Louis","Missouri","63110",{"type":51,"coordinates":101},[102,103],-90.19789,38.62727,{"lat":103,"lon":102},[106,108],{"name":107,"role":35,"phone":37,"phoneExt":37,"email":37},"Asima Badic",{"name":29,"role":35,"phone":37,"phoneExt":37,"email":37},{"facility":110,"status":44,"city":111,"state":112,"zip":113,"country":48,"countryCode":49,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"Foundation for Surgical Innovation","Portland","Oregon","97213",{"type":51,"coordinates":115},[116,117],-122.67621,45.52345,{"lat":117,"lon":116},[120,122],{"name":121,"role":35,"phone":37,"phoneExt":37,"email":37},"Angi Gill",{"name":123,"role":35,"phone":37,"phoneExt":37,"email":37},"Christy Dunst, MD",{"facility":125,"status":44,"city":126,"state":127,"zip":128,"country":48,"countryCode":49,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Benaroya Research Institute at Virginia Mason","Seattle","Washington","98101",{"type":51,"coordinates":130},[131,132],-122.33207,47.60621,{"lat":132,"lon":131},[135,137],{"name":136,"role":35,"phone":37,"phoneExt":37,"email":37},"Cheryl Shaw",{"name":138,"role":35,"phone":37,"phoneExt":37,"email":37},"Pierre Blais, MD",{"type":140,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR","100559144","study-of-enhanced-programming-stimulation-with-the-enterra-therapy-system-100559144",false,"NCT06560307","Study of Enhanced Programming Stimulation with the Enterra® Therapy System","Examination of Programming with the Enterra® Therapy System in a Double-Blinded, Randomized, Prospective Study in the Treatment of Nausea and Vomiting Symptoms Using Gastric Electrical Stimulation","EXPEDITE","Inclusion Criteria:\n\n1. Completed informed consent process with signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged ≥18 or ≤70 years at time of Enterra® therapy implantation\n4. Diagnosed with idiopathic or diabetic gastroparesis\n5. Delayed solid-phase gastric emptying study (Eggbeaters™ test meal), completed within one year of patient enrollment in the study. Gastroparesis defined as \\> 60% retained at 2 hours and\u002For \\>10% retained at 4 hours\n6. Investigator confirms normal endoscopy within one year of enrollment in the study\n7. GCSI-DD score for nausea severity during the qualifying Baseline Period averaging 2.5 or more per week and vomiting averaging 5 or more episodes per week\n\nExclusion Criteria:\n\n1. Post-surgical gastroparesis (e.g., fundoplication, Billroth I or II) or other active stomach or gastrointestinal diseases disorders which could explain symptoms in the opinion of the investigator\n2. History of pyloroplasty or pyloromyotomy or G-POEM\n3. Pregnancy or breastfeeding at the time of consent, or intent to become pregnant during the study\n4. Active H. pylori infection\n5. Significant hepatic injury (elevated ALT, AST, bilirubin)\n6. Metabolic, mechanical, or mucosal inflammatory causes that may explain GI symptoms such as gallbladder disease, small bowel bacterial overgrowth, IBS, inflammatory bowel disease, celiac disease, liver or pancreatic disease, or bowel obstruction\n7. Patients with significant cardiac or cardiovascular disease, malignancy, or other conditions\n8. Participation in other clinical studies\n9. Use of narcotics more than three days per week or other drugs that may affect motility (e.g., Glucagon-like peptide 1 (GLP-1) agonist drug)\n10. Cannabis and\u002For cannabinoid use that exceeds either:\n\n    1. Greater than 3 days of usage per week with 2 or less occurrences each day of use, or\n    2. Greater than 3 grams of total usage per week\n11. Previous diagnosis or history of orthostatic intolerance, e.g., POTS, neurocardiogenic syncope, orthostatic hypotension\n12. Subject experiences discomfort during stimulation assessment that cannot be tolerated\n13. Subjects with an underlying disease leading to follow-up by MRI outside of current MR conditional indications\n14. Evidence of a failed response to temporary gastric electrical stimulation","ALL","18 Years","70 Years",{"count":153,"type":154},50,"ESTIMATED","INTERVENTIONAL",[157],"NA","The purpose of this research study is to evaluate if an enhanced Enterra device programming strategy will improve symptoms associated with gastroparesis, improve symptoms in a faster amount of time, and improve quality of life measures.\n\nParticipants in this study will be evaluated for study entry criteria, have an Enterra Therapy System implanted, and be randomly assigned to one of two programming strategies. Participants will answer daily questions about their gastroparesis symptoms on an application with their phone\u002Ftablet. Participants will answer quality of life questionnaires about their gastroparesis symptoms at monthly study visits.\n\nParticipants will be involved in the study for up to six months after treatment assignment.\n\nProgramming parameters in the study are within currently approved labeling.",[160,161,162],"Gastroparesis","Gastroparesis Nondiabetic","Gastroparesis Due to Diabetes Mellitus",[26,160],"2024-11-13",{"date":166,"type":167},"2024-11-15","ACTUAL",{"date":169,"type":167},"2024-07-25",{"date":171,"type":154},"2026-12",{"name":5,"class":6},6]